Home › Funds › EcoR1 Capital, LLC › LKFT

EcoR1 Capital, LLC position in LKFT

LAKEFRONT BIOTHERAPEUTICS NV

EcoR1 Capital, LLC reported holding 1,667,119 shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV) in its Q2 2026 13F filing — a position valued at US$50.0M, representing 2.57% of its reported portfolio and ranking #8 among its reported holdings. EcoR1 Capital, LLC has disclosed LKFT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.67M sh
Reported value held$49.98M
Portfolio Weight2.57%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How EcoR1 Capital, LLC's LKFT position evolved

EcoR1 Capital, LLC first disclosed a stake in LKFT in Q3 2023 at 5,756,268 shares (US$198.9M). The position peaked in Q4 2023 at 5,756,268 shares, worth US$234.0M. Across 12 filings, EcoR1 Capital, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 1,667,119 shares valued at US$50.0M. Notable position changes include a 97% trim in Q3 2024 (shares fell 4% over the following quarter), a 569% increase in Q2 2025 (shares rose 24% over the following quarter), a 61% increase in Q3 2025 (shares fell 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.76M $198.88M New
Q4 2023 5.76M $233.99M Hold
Q1 2024 5.76M $185.35M Hold
Q2 2024 5.76M $142.64M Hold
Q3 2024 155.01K $4.46M Reduce
Q4 2024 155.01K $4.26M Hold
Q1 2025 155.01K $3.89M Hold
Q2 2025 1.04M $29.02M Add
Q3 2025 1.67M $57.75M Add
Q4 2025 1.67M $54.51M Hold
Q1 2026 1.67M $50.01M Hold
Q2 2026 1.67M $49.98M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LKFT and 13F data

LKFT (LAKEFRONT BIOTHERAPEUTICS NV) is a company whose sector is not yet classified in our data. 17 other funds we track also report a position in LKFT — the largest reported positions include GILEAD SCIENCES, INC. (US$500.2M), TANG CAPITAL MANAGEMENT LLC (US$113.5M), Madison Avenue Partners, LP (US$103.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LKFT

All LKFT fund holders →

FAQ

How long has EcoR1 Capital, LLC held LKFT?

EcoR1 Capital, LLC has disclosed LKFT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is EcoR1 Capital, LLC's current position in LKFT?

As of Q2 2026, EcoR1 Capital, LLC holds 1.67M shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV), valued at $49.98M, representing 2.57% of its reported portfolio and ranking #8.

Has EcoR1 Capital, LLC been buying or selling LKFT?

In the latest 13F filing (Q2 2026), EcoR1 Capital, LLC held unchanged its position in LKFT. The position peaked in Q4 2023 at 5.76M shares.

Which other funds hold LKFT?

Other major institutional holders of LKFT include GILEAD SCIENCES, INC., TANG CAPITAL MANAGEMENT LLC, Madison Avenue Partners, LP, among 17 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.